Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

Annals of Oncology(2022)10.1016/j.annonc.2022.02.001Source: DataRank Database

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 4.9. It has been cited 200 times, with 100 citing works in its 1-hop citation network.

N/A

4.9DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access200 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02393248

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 14.93)OA: hybridTopics (39)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 16%Citation Network 84%

Base Score Contribution

0.795

From this paper's citation signal

Citation Network Contribution

4.1

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
JTO Clinical and Research Reports202311 citations10 referencesContributes 0.248
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Journal of Clinical Oncology2022170 citations28 referencesContributes 0.184
Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment
Oral Oncology20224 citations11 referencesContributes 0.146
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
NEJM Evidence20257 citations15 referencesContributes 0.139
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Clinical Cancer Research202381 citations32 referencesContributes 0.138

Authors (10)

Nicholas Iannotti ORCID,Martin Gutierrez ORCID,David C. Smith ORCID,Luis Féliz ORCID,Christine Lihou ORCID

Live enrichment

PubMed:35176457 PMC:PMC11961695 OpenAlex:https://openalex.org/W4213090323

NCI NIH HHS

Grant: R01 CA242845

NCATS NIH HHS

Grant: UL1 TR000371

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: U01 CA180964

Incyte Corporation

FWCI

14.93

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttp://www.annalsofoncology.org/article/S0923753422001107/pdf

publisherhttp://www.annalsofoncology.org/article/S0923753422001107/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0923753422001107?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0923753422001107?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.annonc.2022.02.001

Fields of Study

Fibroblast Growth Factor ResearchPancreatic and Hepatic Oncology ResearchProteoglycans and glycosaminoglycans research

MeSH Terms

Bile Duct NeoplasmsBile Ducts, IntrahepaticUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Transitional CellFemaleFibroblast Growth FactorsHumansLung NeoplasmsMaleMorpholinesNeoplasm Recurrence, LocalNeoplasmsPyrimidinesPyrrolesReceptors, Fibroblast Growth FactorCholangiocarcinomaProtein Kinase Inhibitors

Keywords

MedicineInternal medicineFibroblast growth factor receptorAdverse effectGastroenterologyPharmacodynamicsMucositisCancerOncologyPharmacokineticsFibroblast growth factorChemotherapyReceptorFgfrAdvanced MalignanciesGenomic ProfilingPhase I/ii Clinical TrialPemigatinib

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 4 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745452.v1figshare

Additional file 4 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745452figshare

Additional file 7 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745467.v1figshare

Additional file 7 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745467figshare

Additional file 6 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745464.v1figshare

Additional file 6 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745464figshare

Additional file 1 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26198881.v1figshare

Additional file 3 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745446.v1figshare

Additional file 3 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745446figshare

Additional file 2 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26198927.v1figshare

Additional file 5 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745458figshare

Additional file 2 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26198927figshare

Additional file 5 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26745458.v1figshare

Additional file 1 of USP8 promotes the tumorigenesis of intrahepatic cholangiocarcinoma via stabilizing OGT

10.6084/m9.figshare.26198881figshare

Related Papers (10)

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

N/A

4.7DataRank · unranked

Journal of Clinical Oncology(2020)

co-cited

10.1200/jco.19.02630

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Clinical Cancer Research(2023)

co-cited

10.1158/1078-0432.ccr-23-1317

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

N/A

0.705DataRank · unranked

Cancer Discovery(2021)

co-cited

10.1158/2159-8290.cd-20-1669

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Annals of Oncology(2022)

co-citedsame journal

10.1016/j.annonc.2022.09.150

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

N/A

4.8DataRank · unranked

Cancer Cell(2021)

co-cited

10.1016/j.ccell.2021.02.014

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

N/A

5.0DataRank · unranked

The Lancet Oncology(2022)

co-cited

10.1016/s1470-2045(22)00541-1

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

N/A

3.9DataRank · unranked

Nature Medicine(2022)

co-cited

10.1038/s41591-022-01931-y

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

N/A

4.0DataRank · unranked

Journal of Clinical Oncology(2022)

co-cited

10.1200/jco.21.01604

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma

Cancer Discovery(2022)

co-cited

10.1158/2159-8290.cd-21-1168

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

N/A

0.689DataRank · unranked

Clinical Cancer Research(2022)

co-cited

10.1158/1078-0432.ccr-21-2664

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (10)

Funding (5 grants)

Impact

Open Access

Topics

Linked Datasets (14)

Annotations (Europe PMC)

Related Papers (10)